{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-091671","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2026-08-06T12:05:35+00:00","discovered_at":"2026-08-06T12:10:00.478232+00:00","generated_at":"2026-08-06T12:10:21.498931+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Edgewise Q2 net loss $57.3M; completes sevasemten sale to Servier for up to $2.65B","bullets":["Net loss $57.3M ($0.53/share) vs $36.1M ($0.34) in Q2 2025; R&D $47.5M, G&A $14.4M.","Completed sale of sevasemten and muscular dystrophy business to Servier for $1.55B upfront + up to $1.1B milestones (closed July 2026).","Cash $460.7M at June 30; pro forma $2.01B after sale proceeds (pre-tax/transaction costs).","Positive top-line Phase 2 CIRRUS-HCM data for EDG-7500 in HCM; Phase 3 expected Q4 2026.","EDG-15400 Phase 1 completed; Phase 2 in HFpEF expected H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-091671","json":"https://secwatch.observer/filing/0001104659-26-091671.json","markdown":"https://secwatch.observer/filing/0001104659-26-091671.md","text":"https://secwatch.observer/filing/0001104659-26-091671.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000110465926091671/0001104659-26-091671-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000110465926091671/tm2621653d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:10:21.498931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}